Indaptus Therapeutics is trading 6.7% down at $2.23, and the reason for the decline remains unclear. - No company announcement dated October 14 was identified; recent company news listings show earlier releases, not a fresh catalyst. - Biotech ETF XBI is down 2.01%, which may contribute, but available evidence does not confirm a direct link to sector weakness or a company event.